149 related articles for article (PubMed ID: 35921465)
1. Oncogene Up-Regulation after Hypomethylating Therapy.
Dekker TJA
N Engl J Med; 2022 Aug; 387(5):476. PubMed ID: 35921465
[No Abstract] [Full Text] [Related]
2. Oncogene Up-Regulation after Hypomethylating Therapy. Reply.
Voso MT; Tenen DG; Chai L
N Engl J Med; 2022 Aug; 387(5):476-477. PubMed ID: 35921466
[No Abstract] [Full Text] [Related]
3. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.
Liu YC; Kwon J; Fabiani E; Xiao Z; Liu YV; Follo MY; Liu J; Huang H; Gao C; Liu J; Falconi G; Valentini L; Gurnari C; Finelli C; Cocco L; Liu JH; Jones AI; Yang J; Yang H; Thoms JAI; Unnikrishnan A; Pimanda JE; Pan R; Bassal MA; Voso MT; Tenen DG; Chai L
N Engl J Med; 2022 May; 386(21):1998-2010. PubMed ID: 35613022
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
Carella AM
Eur J Haematol; 2015 Jun; 94(6):463. PubMed ID: 25702976
[No Abstract] [Full Text] [Related]
5. [Treatment of higher risk myelodysplastic syndromes].
Usuki K
Rinsho Ketsueki; 2019; 60(9):1131-1139. PubMed ID: 31597836
[TBL] [Abstract][Full Text] [Related]
6. Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
Della Porta MG; Alessandrino EP
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1260-1. PubMed ID: 25020100
[No Abstract] [Full Text] [Related]
7. Azacitidine Use for Myeloid Neoplasms.
El Fakih R; Komrokji R; Shaheen M; Almohareb F; Rasheed W; Hassanein M
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e147-e155. PubMed ID: 29478947
[TBL] [Abstract][Full Text] [Related]
8. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure.
Carraway HE
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):470-477. PubMed ID: 27913518
[TBL] [Abstract][Full Text] [Related]
10. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Wang H; Li Y; Lv N; Li Y; Wang L; Yu L
Ann Hematol; 2018 Nov; 97(11):2025-2038. PubMed ID: 30084010
[TBL] [Abstract][Full Text] [Related]
11. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
Silverman LR
Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
[TBL] [Abstract][Full Text] [Related]
13. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
14. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Mongiorgi S; De Stefano A; Ratti S; Indio V; Astolfi A; Casalin I; Pellagatti A; Paolini S; Parisi S; Cavo M; Pession A; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L; Follo MY
Clin Epigenetics; 2023 Feb; 15(1):27. PubMed ID: 36803590
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.
Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Lee WS; Joo YD
Eur J Haematol; 2015 Jun; 94(6):546-53. PubMed ID: 25315896
[TBL] [Abstract][Full Text] [Related]
16. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
17. Improving clinical trials in higher-risk myelodysplastic syndromes.
Sekeres MA
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101406. PubMed ID: 36517123
[TBL] [Abstract][Full Text] [Related]
18. Transplants in myelodysplastic syndromes.
Wetzko K; Platzbecker U
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1011-22. PubMed ID: 25459176
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
20. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
Santini V; Prebet T; Fenaux P; Gattermann N; Nilsson L; Pfeilstöcker M; Vyas P; List AF
Leuk Res; 2014 Dec; 38(12):1381-91. PubMed ID: 25444075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
